Please login to the form below

Not currently logged in
Email:
Password:

FDA gives green light for opioid addiction implant

Titan and Braeburn's Probuphine is first implant of its kind to win US approval
Opioid addiction

The first implant treatment for opioid dependence will be launched in the US shortly following FDA approval for Titan Pharma and Braeburn Pharma's Probuphine.

The biannually administered implant provides a constant, low-level dose of buprenorphine, and is intended for use as part of a maintenance treatment programme for patients already stable on low-to-moderate doses of the drug in other forms.

Probuphine is designed to provide some of the euphoric effects of drugs like heroin, and so minimise withdrawal symptoms and the highs and lows associated with opioid misuse.

An estimated 26.4 - 36 million people suffer from opioid use disorder worldwide, with approximately 2.1 million addicted to prescription opioid pain relievers and a further 467,000 hooked on heroin in the US alone.

Probuphine is the first time that an opioid implant has been given a US license, having been recommended for approval by an FDA panel earlier this year after its manufacturers provided further safety information on its insertion and removal.

The drug provides a new long-acting treatment option for patients with opioid use disorder who previously had to rely on daily doses of pills or dissolvable films - a method vulnerable to the resale of prescribed doses.

Commenting on the approval, FDA commissioner Robert Califf said that such an innovative therapy will help patients to regain control over their lives.

He added: “Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new, innovative treatment options available.”

Probuphine's approval was based on the results of a randomised clinical trial of adults under the age of 65 with a stable opioid dependence.

It found that 63% of patients treated with the Probuphine implant had no evidence of illicit opioid use throughout the six months of treatment.

Nora Volkow, director of the National Institute on Drug Abuse, said: “Scientific evidence suggests that maintenance treatment with these medications in the context of behavioural treatment and recovery support are more effective in the treatment of opioid use disorder than short-term detoxification programmes aimed at abstinence.

“This product will expand the treatment alternatives available to people suffering from an opioid use disorder.”

Article by
Rebecca Clifford

27th May 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...